Cost of new drugs sparks ethical debate

The views of Professor Richard Kefford, co-director of research at the Melanoma Institute Australia – who claimed that drug companies might turn their backs on expensive anti-cancer drug development in the absence of public funding – have been attacked in two letters in this week’s MJA.

One letter, from retired radiation oncologist Graeme Morgan, said a request for funding was “not appropriate for what is effectively a minimally effective palliative treatment”.